Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
respiratory and inhalation
Inhaled drug delivery has several advantages compared to other routes, including rapid onset of action and avoidance of first pass metabolism.
Inhalation drug development requires robust preclinical studies to assess safety, efficacy, and delivery efficiency. Whether developing treatments for respiratory diseases or exploring systemic drug delivery via the lungs, inhalation studies provide essential insights before clinical trials. The inhalation route of biopharmaceutical drug delivery is attractive because of the large surface area of the lung, and close proximity of the alveolar and vascular systems.
Inhalation is of relevance for all therapeutic indications where systemic exposure is desired. There are multiple advantages with inhalation such as rapid onset of action, lower dosing, avoidance of first pass metabolism and potentially fewer side-effects.
Truly Labs has extensive experience of delivery to the lung and offers a wide range of technological solutions and experimental settings for inhalation studies. We have capabilities to conduct single and repeated dosing, using whole-body or nose-only inhalation exposure. Truly Labs is a member of the Medicon Valley Inhalation Consortium and can facilitate access to a broad range of services related to inhalation from early drug discovery to clinical development.
